Could Simcere’s Stanford Medicine IPF deal expose the next big gap in fibrosis treatment?
Find out how Simcere and Stanford Medicine’s IPF collaboration could reshape early-stage antifibrotic drug discovery.
Pharma & Biotech
Pharma & Biotech
Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
Rein Therapeutics advances LTI-03 in Phase 2 IPF trial. Find out what this means for fibrosis drug competition and clinical development today.
Pharma & Biotech
Avalyn Pharma moves AP02 into Phase 2, exploring whether nebulized delivery can improve risk benefit balance in IPF
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Pharma & Biotech
Why Baseimmune’s IPF entry challenges a decade of single-target failure in pulmonary fibrosis
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
Pharma & Biotech
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
Pharma & Biotech
Boehringer Ingelheim expands Jascayd label to PPF following pivotal trial success
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has